CONSOLIDATED STATEMENTS OF CASH FLOW - USD ($)	10 Months Ended	12 Months Ended
	Dec. 31, 2020	Feb. 29, 2020	Feb. 28, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 247,276	$ (134,000)	$ (148,000)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Company expenses paid by Platinum International Biotech Co. Ltd (Cayman Islands) and affiliates	22,298	0	0
Gain from debt extinguishment	(191,000)	0	0
Gain from settlement of accounts payable	(167,000)	0	0
Effect on cash of changes in operating assets and liabilities:
Due to related parties	9,000	0	0
Accrued interest payable to related parties	53,000	0	0
Accounts payable and accrued expenses and other current liabilities	15,426	112,000	116,000
NET CASH USED IN OPERATING ACTIVITIES	(11,000)	(22,000)	(32,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds received from notes payable to related parties-	10,000	19,000	34,000
NET CASH PROVIDED BY FINANCING ACTIVITIES	10,000	19,000	34,000
NET (DECREASE) INCREASE IN CASH	(1,000)	(3,000)	2,000
Beginning of period	1,000	4,000	2,000
End of period	0	1,000	4,000
Supplement disclosure of cash flow information:
Cash paid for interest	0	0	0
Cash paid for income taxes	0	$ 0	$ 0
Non-cash financing activities:
Conversion of notes payable and accrued interest into Class A common shares	1,472,000
Payment of accounts payable and accrued expenses by Activist Investing LLC pursuant to Stock Purchase Agreement dated June 30, 2020	49,000
Company expenses paid by Platinum International Biotech Co. Ltd. (Cayman Islands) and affiliates	$ 22,298